UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-Q/A
(Mark One)
x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2015
or
o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from__________ to _________
Commission File Number 000-52534
PARALLAX HEALTH SCIENCES, INC.
(Exact name of registrant as specified in its charter)
Nevada | 46-4733512 |
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
|
|
1327 Ocean Avenue, Suite B, Santa Monica, CA | 90401 |
(Address of principal executive offices) | (Zip Code) |
|
|
Registrant's telephone number, including area code: | (310) 899-4442 |
|
|
|
|
One Boston Place, Suite 2600, Boston, MA 02108 | |
(Former address, if changed since last report) |
Copy of all Communications to:
Lawrence I. Washor
Washor & Associates
21800 Oxnard Street, Suite 790
Woodland Hills, CA 91367
(310) 479-2660
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
x YES o NO
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).
x YES o NO
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a small reporting company. See the definitions of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer | o |
| Accelerated filer | o |
Non-accelerated filer | o |
| Smaller reporting company | x |
(Do not check if a smaller reporting company) |
|
|
|
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act)
o YES x NO
APPLICABLE ONLY TO CORPORATE ISSUERS
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.
132,026,053 common shares issued and outstanding as of August 15, 2015
EXPLANATORY NOTE
This Amendment No. 1 to the Quarterly Report on Form 10-Q/A is being filed solely to furnish the Interactive Data files as Exhibit 101, in accordance with Rule 405 of Regulation S-T. No other changes have been made to the Form 10-Q, as originally filed on August 19, 2015.
ITEM 6. EXHIBITS
Exhibits required by Item 601 of Regulation S-B
Exhibit Number | Description of Exhibit | Filing Reference |
(100) | XBRL Related Documents | |
101.INS** | XBRL Instance Document | Filed herewith. |
101.SCH** | XBRL Taxonomy Extension Schema Document | Filed herewith. |
101.CAL** | XBRL Taxonomy Extension Calculation Linkbase Document | Filed herewith. |
101.LAB** | XBRL Taxonomy Extension Labels Linkbase Document | Filed herewith. |
101.PRE** | XBRL Taxonomy Extension Presentation Linkbase Document | Filed herewith. |
101.DEF** | XBRL Taxonomy Extension Definition Linkbase Document | Filed herewith. |
*
Filed herewith.
**
Pursuant to Rule 406T of Regulation S-T, these interactive data files are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| PARALLAX HEALTH SCIENCES, INC. |
|
|
|
|
Dated: August 24, 2015 | /s/ J. Michael Redmond |
| J. Michael Redmond |
| President, Chief Executive Officer and Director |
|
|
|
|
|
|
Dated: August 24, 2015 | /s/ Calli Bucci |
| Calli Bucci |
| Chief Financial Officer |